: iStockAnalyst.com Symbols Feed

Celgene (NASDAQ:CELG): Selloff Opportunity

Mon, 06 Apr 2009 16:46:11 GMT

After warning that Celgene (NASDAQ: CELG) would only achieve the low end of its previous guidance range for 2009, the stock of the company sold off significantly, noted biotech expert John McCamant.[More...]

SEC Charges Professionals With Insider Trading

Fri, 26 Dec 2008 15:46:00 GMT

The Securities and Exchange Commission (SEC), concerned about its recent bad press, continues to prosecute insider trading through the Christmas season. Last week, the regulatory body charged seven individuals and two companies involved in an insider trading ring. The SEC alleged that Matthew Devlin, formerly of Lehman Brothers, traded on and tipped his clients and friends with confidential and non-public information about 13 impending corporate transactions. Some of these friends, who worked in the financial or legal professions, also tipped off other clients. Devlin obtained the privileged information from his wife, a partner in the NYC office of an international public relations firm working on the deals. The illicit trading occurred from at least March 2004 through July 2008, yielding more than $4.8 million in profits. Devlin was also rewarded with cash and luxury items in exchange for the information, including a widescreen TV,[More...]

Analyst Comments: Joy Global, Photronics, Martha Stewart, Kellogg, Red Robin, Cirrus Logic, Safeway, PACCAR, Celgene, AstraZeneca, Phase Forward, Digital River, Methanex, Grupo Televisa, HSBC, AAR Corp, Centennial, Carmike Cinema, Washington Post

Fri, 10 Oct 2008 14:05:00 GMT

We are maintaining our Buy recommendation on Joy Global (JOYG). The global coal market appears strong as supply and demand fundamentals should keep prices elevated for the next several years. This will be a benefit to Joy as it is the world's leading manufacturer of mining machinery in the world. Sales and bookings were impressive in Q3 reflecting producer's positive long-term outlook for coal prices. Joy's industry leading operating margins look to improve on the back of several cost cutting and capacity expansion initiatives that will be felt as early as 2009. However we are lowering our target price from $84.00 to $71.00 per share due contraction of our valuation multiples. Although already an industry leader in operating margins, the growth and cost initiatives put in place will pave the way for higher revenues, margins and[More...]

Morning Digest for 4/18

Fri, 18 Apr 2008 14:05:53 GMT

Submitted By Optiondragon[More...]

Analyst Comments: NVIDIA, Health Care Properties, Avanex, Pharmion, Citizens

Thu, 21 Feb 2008 15:02:45 GMT

As the only remaining major independent player in the market for Graphic Processing Units (GPUs) used in PCs, NVIDIA Corporation (NVDA) is well positioned to benefit from increased graphics requirements with strong momentum in its GeForce products. NVIDIA[More...]

100 Stocks That Made Money This Year

Mon, 21 Jan 2008 11:42:13 GMT

This has been the worst stock market start for US equities in... history. So instead of doing the weekly look at what is winning let's see what has been able to eek out a gain this year. Amazingly out of the entire universe of stocks with market cap of $2 billion or more, only 100 have a return >1%. 100 lonely souls. (and a couple at the top of the list seem like old acquisitions so they could be errors) About 10% of the list is the same theme.... you can see what I've highlighted....Market cap >$2 BillionAverage trading volume >100KStock Price >$10 [More...]

Huge Drop

Fri, 18 Jan 2008 08:35:53 GMT

Major indices posted another huge loss after mountains of bad news. The Philadelphia Fed showed the lowest numbers since 2001 and MER posted very...[More...]

Celgene (NASDAQ:CELG): Stock looks bottomed - Citigroup

Thu, 03 Jan 2008 19:07:40 GMT

Citigroup is out positive on Celgene (NASDAQ:CELG) reiterating BUy and $82 tgt after the co announced that the 30-day period for the Federal Trade Commission (FTC) review of its proposed merger with Pharmion under the Hart-Scott-Rodino...[More...]

Cara's Daily Report, Tues., Nov 20, 2007

Tue, 20 Nov 2007 14:14:01 GMT

Markets Re-capThere will likely be a difference between yesterday and today, particularly at the open.On Monday, the DJIA suffered its fourth 200+ point decline in November. The Dow 30 (-218.35), S&P 500 (-25.47), and Nasdaq Composite (-43.86) all got caught up in the plight of the Big Banks.Concerns about Citigroup (C) after Goldman Sachs cut their rating from Neutral to Sell, citing Citi's exposure to CDO's, and the general weakness in the economy expressed by bankers and central bankers, weighed heavily. In addition, the NAHB Housing Market Index remained unchanged at 19, indicating the house builders believe that market conditions have not improved. On the earning’s front, Lowe's (LOW) reported a -10 pct decrease in fiscal 3Q net earnings to $643 million vs $716 million a year ago, due to continued housing industry troubles. Then, after the bell, Hewlett-Packard (HPQ) reported 4Q earnings of $2.2 billion vs $1.7[More...]

Monday Morning - Nov 19 2007 10:21AM

Mon, 19 Nov 2007 14:16:00 GMT

Following Friday's surprising late-session rally, futures indicate a lower open for the mkt amid weakness in Asia, a downgrade of Citigroup (C) and a Q4 earnings warning from home improvement retailer Lowe's (LOW). Dow futures are currently ; Nasdaq futures are currently ; S&P futures are currently . Mkts in Asia closed lower after China's banking regulator told banks to cool loan growth that's already topped its target ceiling of 15% this year. Note, though, that the WSJ reported this morning that Chinese regulators have actually ordered China's commercial banks to freeze lending through the end of the year. In the financial sector, Goldman Sachs downgraded Citigroup to Sell, while cutting its price ests on a number of brokers, including MER, MS, LEH, BSC, JPM and ETFC. It's also worth noting that the Sunday Times reported over the weekend that Royal Bank of Scotland (RBS) CEO Fred Goodwin has been informally approached by Citigroup to become its new CEO. Lowe's reported mixed[More...]

Boulder-Based Clovis' $146.3M Financing Largest in U.S.

Wed, 22 Jul 2009 14:54:00 GMT

Jul. 22--BOULDER, Colo. -- The Boulder oncology startup founded by Pharmion Corp. veterans raised the largest amount of venture capital funding in the nation during the second quarter, when it landed more than $145 million in initial equity funding, according to a quarterly report released Monday.
Clovis Oncology -- launched in May and created to acquire, develop and commercialize anti-cancer agents -- raised $146.3 million, making it the largest deal-maker in the United States for the second quarter, according to the PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters.
Officials for Clovis could not be reached for comment.

[More...]

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Fri, 09 Nov 2007 17:48:00 GMT

Pharmion Corporation today released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer . Amrubicin, the company's third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC. These findings indicate favorable interim results in terms of response rate and survival for Amrubicin in second-line treatment of small-cell lung cancer patients with extensive disease SCLC. The early results of this study were presented at the 2007 Chemotherapy Foundation Symposium today in New York City.[More...]

Pharmion Corporation Reports 2007 Third Quarter Operating Results

Wed, 31 Oct 2007 19:56:00 GMT

Pharmion Corporation today reported financial results for its quarter ended September 30, 2007. Third quarter net sales totaled $67.3 million, compared to $61.6 million in the third quarter of 2006. Worldwide sales of Vidaza totaled $42.3 million in the third quarter of 2007, compared to $36.6 million in the same quarter of 2006. In the U.S., sales of Vidaza totaled $33.3 million in the third quarter of 2007, equal to the same quarter of 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $9.0 million in the third quarter of 2007, compared to $3.3 million in the third quarter of 2006. Sales of Thalidomide, including named patient and compassionate use sales in Europe, totaled $20.2 million in the third quarter of 2007, also equal to the same period of 2006.[More...]

Form 4 PHARMION CORP For: Mar 07 Filed by: McKinley Edward J (10K)

Fri, 25 Jul 2008 20:17:00 GMT

[More...]